|
|
Article: HGS LICENSES TWO TARGETS TO SCHERING-PLOUGH, FULFILLS DUTIES.(Brief Article)
- Article from:
- BIOWORLD Today
- Article date:
- July 25, 2002
- Author:
CopyrightCOPYRIGHT 2002 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Schering-Plough Corp. acquired exclusive rights to two human antibodies derived from Human Genome Sciences Inc.'s technology, thereby completing HGS's obligations to Schering as defined by the Human Gene Therapeutic Consortium.
HGS would receive milestone payments and royalties from products that result from either antibody. Schering-Plough, of Madison, N.J., had options to two therapeutic proteins, one of which it picked up in October 2000, deciding to develop and commercialize a type of interferon. That left Schering-Plough with one protein option.
"Rather than retain [its] additional option, we granted Schering- Plough exclusive licenses to two ...